期刊文献+

非诺贝特对高三酰甘油血症患者血压、肱动脉舒张值的影响 被引量:4

下载PDF
导出
摘要 目的观察非诺贝特联合降压治疗对高血压合并高三酰甘油血症患者血压、血流介导的肱动脉舒张值的影响。方法62例合并高三酰甘油血症的原发性高血压患者随机分为调脂饮食加坎地沙坦加非诺贝特组(A组),调脂饮食加坎地沙坦加安慰剂组(B组)。观察两组血压及血流介导的肱动脉舒张值的变化。结果两组治疗后收缩压和舒张压均显著下降(P<0.01),A组较B组能更显著降低收缩压和舒张压(P<0.01)。A组能显著降低总胆固醇、三酰甘油及低密度脂蛋白胆固醇水平,增加高密度脂蛋白胆固醇水平(P<0.01),而B组在治疗前后脂质谱无显著改善(P>0.05)。两组治疗后血流介导的肱动脉舒张值明显增加(P<0.01),A组较B组能更显著增加血流介导的肱动脉舒张值(P<0.01)。结论非诺贝特可能通过改善血脂代谢紊乱,在降压药物的基础上,进一步改善患者的血管内皮功能,并且对患者血压有协同降低作用。
出处 《中西医结合心脑血管病杂志》 2008年第11期1278-1279,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献15

  • 1Bakris GL, Tarka EA, Waterhouse B,et al. Cardiovascular risk factors in hypertension:Rationale and design of studies to investigate the effects of controlled - release carvedilol on regression of left ventricular hypertrophy and lipid profile [J]. Am J Cardiol, 2006. 98(7A): 46L- 52L.
  • 2Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group[J]. Arch Intern Med,1992,152(7):1490 - 1500.
  • 3Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients[J ]. Circulation, 2004,110 (24) : 3687 - 3692.
  • 4Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients[J]. Diabetes Care, 2006, 29 (2): 195-201.
  • 5Celermajer DS, Sorensen KE, Bull C, et al. Endothelium - de pendent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction[J]. J Am Coll Cardiol, 1994, 24(8): 1468-1474.
  • 6Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia[J]. J Am Coll Cardiol, 2005,45 (10) : 1649 - 1653.
  • 7Perticone F, Maio R, Sciacqua A, et al. Endothelial dysfunction and C reactive protein are risk factors for diabetes in essential hypertension[J]. Diabetes, 2008, 57(1) : 167 - 171.
  • 8Karpov RS, Koshel skaia OA, Suslova TE, el al. Effect of 6 - month therapy with sirnvastatin on lipid transport function of the blood and the state of endothelium in patients with diabetes and hypertension[J]. Cardiologiia, 2006, 46(1): 27-31.
  • 9Chehrei A, Sadrnia S, Samanianpour P, et al. Lipid profile cutoff values for predicting hypertension in an iranian population (ROC curve analysis)[J]. Med Sci Monit,2007,13(2) :100 - 104.
  • 10Irace C, Tschakovsky ME, Carallo C,et al. Endothelial dysfunction or dysfunctions? Identification of three different FMD responses in males with type 2 diabetes[J]. Atherosclerosis, 2008 18(6) :29 - 32.

二级参考文献3

共引文献10

同被引文献41

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部